Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
23 December 2013 |
Main ID: |
EUCTR2007-005455-42-NL |
Date of registration:
|
18/09/2008 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
ENDO ACE TRIAL
Endoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn´s disease with or without additive local steroid injection and oral Budenofalk;
a randomized controlled trial
- ENDO ACE TRIAL
|
Scientific title:
|
ENDO ACE TRIAL
Endoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn´s disease with or without additive local steroid injection and oral Budenofalk;
a randomized controlled trial
- ENDO ACE TRIAL |
Date of first enrolment:
|
26/02/2009 |
Target sample size:
|
42 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005455-42 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
Netherlands
| | | | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Informed consent
• Man or woman between 18 and 75 years of age
• Established diagnosis of Crohn’s disease
Negative stool culture (for exclusion of infectious ileocolitis and Clostridium Difficile infection)
• History of ileocecal resection
• = 2 symptoms of intestinal obstruction
- Intermittent abdominal pain
- Abdominal distension
- Nausea
- Vomiting
- Anorexia
• Significant stenotic segment (defined as a decrease in calibre of the intestinal lumen with or without a pre-stenotic dilatation) located at the anastomosis as diagnosed with MR enterography and abdominal ultrasound.
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: • A stenotic segment of more than 5 cm
• Rutgeerts score i4 inflammation at the site of stenosis
• Fistulas at the site of stenosis or in the near proximity
• A stenosis that cannot be properly endoscopically visualized
• A significant stenosis proximal to the stenotic anastomosis
• The concomitant use of other oral drugs containing budesonide within 4 weeks of screening
• Pregnancy, lactation, or intended pregnancy within 9 months
• Serious secondary illnesses of an acute or chronic nature (e.g., acute cardiovascular disease, active infection)
• Known intolerance/hypersensitivity to the study drug
• Well-founded doubt about the patient’s cooperation and/or compliance
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Crohn's disease.
Patients with Crohn's disease with status after ileocecal resection. Stenotic ileocecal anastomosis with symptoms of obstruction. MedDRA version: 14.1
Level: PT
Classification code 10011401
Term: Crohn's disease
System Organ Class: 10017947 - Gastrointestinal disorders
|
Intervention(s)
|
Trade Name: Budenofalk Product Name: Budenofalk Pharmaceutical Form: Capsule, soft INN or Proposed INN: BUDESONIDE CAS Number: 51333223 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3 -mg Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use
Trade Name: Kenacort Product Name: Kenacort Pharmaceutical Form: Solution for injection INN or Proposed INN: TRIAMCINOLONE CAS Number: 124947 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40-mg/ml Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intraileal use (Noncurrent)
|
Primary Outcome(s)
|
Primary end point(s): To evaluate whether the addition of intensive local anti-inflammatory therapy reduces the recurrence of stenosis and/or need for surgical intervention in routine enteric balloon dilatation in Crohn´s disease patients with symptomatic stenosis of the anastomosis.
|
Main Objective: The primary objective of this study is to evaluate the benefit of adding intensive local anti-inflammatory therapy (Triamcinolone injection therapy combined with 9 mg oral BudenoFalk once daily for 24 weeks) to routine enteric balloon dilatation in Crohn´s disease patients with symptomatic anastomosis
|
Secondary Objective: To assess the feasibility and value of radiologic imaging of the anastomosis in the endoscopy suite, and validating Radiological Crohn´s Disease Anastomotic Index (RCDAI).
|
Secondary ID(s)
|
IBD-ENDO-2008-1
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|